0001564590-21-032783.txt : 20210614 0001564590-21-032783.hdr.sgml : 20210614 20210614162031 ACCESSION NUMBER: 0001564590-21-032783 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210611 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20210614 DATE AS OF CHANGE: 20210614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 211014829 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20210611.htm 8-K adpt-8k_20210611.htm
false 0001478320 0001478320 2021-06-11 2021-06-11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2021

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1551 Eastlake Avenue East, Suite 200,

Seattle, Washington

 

98102

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 


 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 11, 2021, Adaptive Biotechnologies Corporation (the “Company”) held its annual meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on four proposals, as described below. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 23, 2021. The vote totals noted below are final voting results from the Annual Meeting.

 

1.

The Company’s shareholders elected the following three Class II director nominees, each to hold office until the 2024 annual meeting of shareholders or until his or her successor is elected and qualified, by the vote set forth below:

 

Nominee

 

Votes For

 

Votes

Withheld

 

Broker

Non-Votes

Michelle Griffin

 

95,779,979

 

12,600,796

 

14,450,327

Peter Neupert

 

92,865,432

 

15,515,343

 

14,450,327

Leslie Trigg

 

97,812,160

 

10,568,615

 

14,450,327

 

 

2.

The Company’s shareholders approved, on a non-binding advisory basis, the 2020 compensation of its named executive officers as described in the proxy statement based on the following results:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker

Non-Votes

100,345,226

 

7,888,977

 

146,572

 

14,450,327

 

 

3.

The Company’s shareholders approved, on a non-binding advisory basis, a frequency of one year for future advisory votes on named executive officers’ compensation. After considering these results, we will hold a non-binding advisory vote on executive compensation on an annual basis until the next advisory vote on the frequency of non-binding votes on executive compensation.

 

One Year

 

Two Years

 

Three Years

 

Abstentions

 

Broker

Non-Votes

107,470,826

 

18,789

 

870,697

 

20,461

 

14,450,327

 

4.

The Company’s shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 by the vote set forth below:

 

Votes For

 

Votes Against

 

Abstentions

122,794,811

 

21,326

 

14,964

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: June 14, 2021

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

 

EX-101.SCH 2 adpt-20210611.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 adpt-20210611_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 adpt-20210611_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 adpt-8k_20210611_htm.xml IDEA: XBRL DOCUMENT 0001478320 2021-06-11 2021-06-11 false 0001478320 8-K 2021-06-11 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1551 Eastlake Avenue East Suite 200 Seattle WA 98102 206 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Jun. 11, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2021
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Emerging Growth Company false
Entity File Number 001-38957
Entity Incorporation, State or Country Code WA
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1551 Eastlake Avenue East
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20210611.htm adpt-20210611.xsd adpt-20210611_lab.xml adpt-20210611_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20210611.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "adpt-8k_20210611.htm" ] }, "labelLink": { "local": [ "adpt-20210611_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "adpt-20210611_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "adpt-20210611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20210611", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210611.htm", "contextRef": "C_0001478320_20210611_20210611", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210611.htm", "contextRef": "C_0001478320_20210611_20210611", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-21-032783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-032783-xbrl.zip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
  •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end